A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
Background Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survi...
Saved in:
| Published in | BMC cancer Vol. 18; no. 1; pp. 596 - 9 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
25.05.2018
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-2407 1471-2407 |
| DOI | 10.1186/s12885-018-4453-z |
Cover
Loading…
| Abstract | Background
Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survival (OS). HF10 is a spontaneously mutated oncolytic virus derived from a herpes simplex virus-1, and it has potential to show strong antitumor effect against malignancies without damaging normal tissue. We aimed to evaluate the safety and anti-tumor effectiveness in phase I dose-escalation trial of direct injection of HF10 into unresectable locally advanced pancreatic cancer under endoscopic ultrasound (EUS)-guidance in combination with erlotinib and gemcitabine administration. The mid-term results have been previously reported and here we report the final results of our study.
Methods
This was a single arm, open-label Phase I trial. HF10 was injected once every 2 weeks and continued up to four times in total unless dose-limiting toxicity (DLT) appears. A total of nine subjects in three Cohorts with dose-escalation were planned to be enrolled in this trial. The primary endpoint was the safety assessment and the secondary endpoint was the efficacy assessment.
Results
Twelve patients enrolled in this clinical trial, and ten subjects received this therapy. Five patients showed Grade III myelosuppression and two patients developed serious adverse events (AEs) (perforation of duodenum, hepatic dysfunction). However, all of these events were judged as AEs unrelated to HF10. Tumor responses were three partial responses (PR), four stable diseases (SD), and two progressive diseases (PD) out of nine subjects who completed the treatment. Target lesion responses were three PRs and six SDs. The median progression free survival (PFS) was 6.3 months, whereas the median OS was 15.5 months. Two subjects from Cohort 1 and 2 showed downstaging and finally achieved surgical complete response (CR).
Conclusions
HF10 direct injection under EUS-guidance in combination with erlotinib and gemcitabine was a safe treatment for locally advanced pancreatic cancer. Combination therapy of HF10 and chemotherapy should be explored further in large prospective studies. Trial registration: This study was prospectively registered in UMIN-CTR (UMIN000010150) on March 4th, 2013. |
|---|---|
| AbstractList | Background
Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survival (OS). HF10 is a spontaneously mutated oncolytic virus derived from a herpes simplex virus-1, and it has potential to show strong antitumor effect against malignancies without damaging normal tissue. We aimed to evaluate the safety and anti-tumor effectiveness in phase I dose-escalation trial of direct injection of HF10 into unresectable locally advanced pancreatic cancer under endoscopic ultrasound (EUS)-guidance in combination with erlotinib and gemcitabine administration. The mid-term results have been previously reported and here we report the final results of our study.
Methods
This was a single arm, open-label Phase I trial. HF10 was injected once every 2 weeks and continued up to four times in total unless dose-limiting toxicity (DLT) appears. A total of nine subjects in three Cohorts with dose-escalation were planned to be enrolled in this trial. The primary endpoint was the safety assessment and the secondary endpoint was the efficacy assessment.
Results
Twelve patients enrolled in this clinical trial, and ten subjects received this therapy. Five patients showed Grade III myelosuppression and two patients developed serious adverse events (AEs) (perforation of duodenum, hepatic dysfunction). However, all of these events were judged as AEs unrelated to HF10. Tumor responses were three partial responses (PR), four stable diseases (SD), and two progressive diseases (PD) out of nine subjects who completed the treatment. Target lesion responses were three PRs and six SDs. The median progression free survival (PFS) was 6.3 months, whereas the median OS was 15.5 months. Two subjects from Cohort 1 and 2 showed downstaging and finally achieved surgical complete response (CR).
Conclusions
HF10 direct injection under EUS-guidance in combination with erlotinib and gemcitabine was a safe treatment for locally advanced pancreatic cancer. Combination therapy of HF10 and chemotherapy should be explored further in large prospective studies. Trial registration: This study was prospectively registered in UMIN-CTR (UMIN000010150) on March 4th, 2013. Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survival (OS). HF10 is a spontaneously mutated oncolytic virus derived from a herpes simplex virus-1, and it has potential to show strong antitumor effect against malignancies without damaging normal tissue. We aimed to evaluate the safety and anti-tumor effectiveness in phase I dose-escalation trial of direct injection of HF10 into unresectable locally advanced pancreatic cancer under endoscopic ultrasound (EUS)-guidance in combination with erlotinib and gemcitabine administration. The mid-term results have been previously reported and here we report the final results of our study. This was a single arm, open-label Phase I trial. HF10 was injected once every 2 weeks and continued up to four times in total unless dose-limiting toxicity (DLT) appears. A total of nine subjects in three Cohorts with dose-escalation were planned to be enrolled in this trial. The primary endpoint was the safety assessment and the secondary endpoint was the efficacy assessment. Twelve patients enrolled in this clinical trial, and ten subjects received this therapy. Five patients showed Grade III myelosuppression and two patients developed serious adverse events (AEs) (perforation of duodenum, hepatic dysfunction). However, all of these events were judged as AEs unrelated to HF10. Tumor responses were three partial responses (PR), four stable diseases (SD), and two progressive diseases (PD) out of nine subjects who completed the treatment. Target lesion responses were three PRs and six SDs. The median progression free survival (PFS) was 6.3 months, whereas the median OS was 15.5 months. Two subjects from Cohort 1 and 2 showed downstaging and finally achieved surgical complete response (CR). HF10 direct injection under EUS-guidance in combination with erlotinib and gemcitabine was a safe treatment for locally advanced pancreatic cancer. Combination therapy of HF10 and chemotherapy should be explored further in large prospective studies. This study was prospectively registered in UMIN-CTR (UMIN000010150) on March 4th, 2013. Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survival (OS). HF10 is a spontaneously mutated oncolytic virus derived from a herpes simplex virus-1, and it has potential to show strong antitumor effect against malignancies without damaging normal tissue. We aimed to evaluate the safety and anti-tumor effectiveness in phase I dose-escalation trial of direct injection of HF10 into unresectable locally advanced pancreatic cancer under endoscopic ultrasound (EUS)-guidance in combination with erlotinib and gemcitabine administration. The mid-term results have been previously reported and here we report the final results of our study.BACKGROUNDPrognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survival (OS). HF10 is a spontaneously mutated oncolytic virus derived from a herpes simplex virus-1, and it has potential to show strong antitumor effect against malignancies without damaging normal tissue. We aimed to evaluate the safety and anti-tumor effectiveness in phase I dose-escalation trial of direct injection of HF10 into unresectable locally advanced pancreatic cancer under endoscopic ultrasound (EUS)-guidance in combination with erlotinib and gemcitabine administration. The mid-term results have been previously reported and here we report the final results of our study.This was a single arm, open-label Phase I trial. HF10 was injected once every 2 weeks and continued up to four times in total unless dose-limiting toxicity (DLT) appears. A total of nine subjects in three Cohorts with dose-escalation were planned to be enrolled in this trial. The primary endpoint was the safety assessment and the secondary endpoint was the efficacy assessment.METHODSThis was a single arm, open-label Phase I trial. HF10 was injected once every 2 weeks and continued up to four times in total unless dose-limiting toxicity (DLT) appears. A total of nine subjects in three Cohorts with dose-escalation were planned to be enrolled in this trial. The primary endpoint was the safety assessment and the secondary endpoint was the efficacy assessment.Twelve patients enrolled in this clinical trial, and ten subjects received this therapy. Five patients showed Grade III myelosuppression and two patients developed serious adverse events (AEs) (perforation of duodenum, hepatic dysfunction). However, all of these events were judged as AEs unrelated to HF10. Tumor responses were three partial responses (PR), four stable diseases (SD), and two progressive diseases (PD) out of nine subjects who completed the treatment. Target lesion responses were three PRs and six SDs. The median progression free survival (PFS) was 6.3 months, whereas the median OS was 15.5 months. Two subjects from Cohort 1 and 2 showed downstaging and finally achieved surgical complete response (CR).RESULTSTwelve patients enrolled in this clinical trial, and ten subjects received this therapy. Five patients showed Grade III myelosuppression and two patients developed serious adverse events (AEs) (perforation of duodenum, hepatic dysfunction). However, all of these events were judged as AEs unrelated to HF10. Tumor responses were three partial responses (PR), four stable diseases (SD), and two progressive diseases (PD) out of nine subjects who completed the treatment. Target lesion responses were three PRs and six SDs. The median progression free survival (PFS) was 6.3 months, whereas the median OS was 15.5 months. Two subjects from Cohort 1 and 2 showed downstaging and finally achieved surgical complete response (CR).HF10 direct injection under EUS-guidance in combination with erlotinib and gemcitabine was a safe treatment for locally advanced pancreatic cancer. Combination therapy of HF10 and chemotherapy should be explored further in large prospective studies.CONCLUSIONSHF10 direct injection under EUS-guidance in combination with erlotinib and gemcitabine was a safe treatment for locally advanced pancreatic cancer. Combination therapy of HF10 and chemotherapy should be explored further in large prospective studies.This study was prospectively registered in UMIN-CTR (UMIN000010150) on March 4th, 2013.TRIAL REGISTRATIONThis study was prospectively registered in UMIN-CTR (UMIN000010150) on March 4th, 2013. Background Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survival (OS). HF10 is a spontaneously mutated oncolytic virus derived from a herpes simplex virus-1, and it has potential to show strong antitumor effect against malignancies without damaging normal tissue. We aimed to evaluate the safety and anti-tumor effectiveness in phase I dose-escalation trial of direct injection of HF10 into unresectable locally advanced pancreatic cancer under endoscopic ultrasound (EUS)-guidance in combination with erlotinib and gemcitabine administration. The mid-term results have been previously reported and here we report the final results of our study. Methods This was a single arm, open-label Phase I trial. HF10 was injected once every 2 weeks and continued up to four times in total unless dose-limiting toxicity (DLT) appears. A total of nine subjects in three Cohorts with dose-escalation were planned to be enrolled in this trial. The primary endpoint was the safety assessment and the secondary endpoint was the efficacy assessment. Results Twelve patients enrolled in this clinical trial, and ten subjects received this therapy. Five patients showed Grade III myelosuppression and two patients developed serious adverse events (AEs) (perforation of duodenum, hepatic dysfunction). However, all of these events were judged as AEs unrelated to HF10. Tumor responses were three partial responses (PR), four stable diseases (SD), and two progressive diseases (PD) out of nine subjects who completed the treatment. Target lesion responses were three PRs and six SDs. The median progression free survival (PFS) was 6.3 months, whereas the median OS was 15.5 months. Two subjects from Cohort 1 and 2 showed downstaging and finally achieved surgical complete response (CR). Conclusions HF10 direct injection under EUS-guidance in combination with erlotinib and gemcitabine was a safe treatment for locally advanced pancreatic cancer. Combination therapy of HF10 and chemotherapy should be explored further in large prospective studies. Trial registration: This study was prospectively registered in UMIN-CTR (UMIN000010150) on March 4th, 2013. Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survival (OS). HF10 is a spontaneously mutated oncolytic virus derived from a herpes simplex virus-1, and it has potential to show strong antitumor effect against malignancies without damaging normal tissue. We aimed to evaluate the safety and anti-tumor effectiveness in phase I dose-escalation trial of direct injection of HF10 into unresectable locally advanced pancreatic cancer under endoscopic ultrasound (EUS)-guidance in combination with erlotinib and gemcitabine administration. The mid-term results have been previously reported and here we report the final results of our study. This was a single arm, open-label Phase I trial. HF10 was injected once every 2 weeks and continued up to four times in total unless dose-limiting toxicity (DLT) appears. A total of nine subjects in three Cohorts with dose-escalation were planned to be enrolled in this trial. The primary endpoint was the safety assessment and the secondary endpoint was the efficacy assessment. Twelve patients enrolled in this clinical trial, and ten subjects received this therapy. Five patients showed Grade III myelosuppression and two patients developed serious adverse events (AEs) (perforation of duodenum, hepatic dysfunction). However, all of these events were judged as AEs unrelated to HF10. Tumor responses were three partial responses (PR), four stable diseases (SD), and two progressive diseases (PD) out of nine subjects who completed the treatment. Target lesion responses were three PRs and six SDs. The median progression free survival (PFS) was 6.3 months, whereas the median OS was 15.5 months. Two subjects from Cohort 1 and 2 showed downstaging and finally achieved surgical complete response (CR). HF10 direct injection under EUS-guidance in combination with erlotinib and gemcitabine was a safe treatment for locally advanced pancreatic cancer. Combination therapy of HF10 and chemotherapy should be explored further in large prospective studies. Trial registration: This study was prospectively registered in UMIN-CTR (UMIN000010150) on March 4th, 2013. Background Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survival (OS). HF10 is a spontaneously mutated oncolytic virus derived from a herpes simplex virus-1, and it has potential to show strong antitumor effect against malignancies without damaging normal tissue. We aimed to evaluate the safety and anti-tumor effectiveness in phase I dose-escalation trial of direct injection of HF10 into unresectable locally advanced pancreatic cancer under endoscopic ultrasound (EUS)-guidance in combination with erlotinib and gemcitabine administration. The mid-term results have been previously reported and here we report the final results of our study. Methods This was a single arm, open-label Phase I trial. HF10 was injected once every 2 weeks and continued up to four times in total unless dose-limiting toxicity (DLT) appears. A total of nine subjects in three Cohorts with dose-escalation were planned to be enrolled in this trial. The primary endpoint was the safety assessment and the secondary endpoint was the efficacy assessment. Results Twelve patients enrolled in this clinical trial, and ten subjects received this therapy. Five patients showed Grade III myelosuppression and two patients developed serious adverse events (AEs) (perforation of duodenum, hepatic dysfunction). However, all of these events were judged as AEs unrelated to HF10. Tumor responses were three partial responses (PR), four stable diseases (SD), and two progressive diseases (PD) out of nine subjects who completed the treatment. Target lesion responses were three PRs and six SDs. The median progression free survival (PFS) was 6.3 months, whereas the median OS was 15.5 months. Two subjects from Cohort 1 and 2 showed downstaging and finally achieved surgical complete response (CR). Conclusions HF10 direct injection under EUS-guidance in combination with erlotinib and gemcitabine was a safe treatment for locally advanced pancreatic cancer. Combination therapy of HF10 and chemotherapy should be explored further in large prospective studies. Trial registration: This study was prospectively registered in UMIN-CTR (UMIN000010150) on March 4th, 2013. Keywords: Pancreatic cancer, Oncolytic virus, HF10, EUS-guidance Abstract Background Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survival (OS). HF10 is a spontaneously mutated oncolytic virus derived from a herpes simplex virus-1, and it has potential to show strong antitumor effect against malignancies without damaging normal tissue. We aimed to evaluate the safety and anti-tumor effectiveness in phase I dose-escalation trial of direct injection of HF10 into unresectable locally advanced pancreatic cancer under endoscopic ultrasound (EUS)-guidance in combination with erlotinib and gemcitabine administration. The mid-term results have been previously reported and here we report the final results of our study. Methods This was a single arm, open-label Phase I trial. HF10 was injected once every 2 weeks and continued up to four times in total unless dose-limiting toxicity (DLT) appears. A total of nine subjects in three Cohorts with dose-escalation were planned to be enrolled in this trial. The primary endpoint was the safety assessment and the secondary endpoint was the efficacy assessment. Results Twelve patients enrolled in this clinical trial, and ten subjects received this therapy. Five patients showed Grade III myelosuppression and two patients developed serious adverse events (AEs) (perforation of duodenum, hepatic dysfunction). However, all of these events were judged as AEs unrelated to HF10. Tumor responses were three partial responses (PR), four stable diseases (SD), and two progressive diseases (PD) out of nine subjects who completed the treatment. Target lesion responses were three PRs and six SDs. The median progression free survival (PFS) was 6.3 months, whereas the median OS was 15.5 months. Two subjects from Cohort 1 and 2 showed downstaging and finally achieved surgical complete response (CR). Conclusions HF10 direct injection under EUS-guidance in combination with erlotinib and gemcitabine was a safe treatment for locally advanced pancreatic cancer. Combination therapy of HF10 and chemotherapy should be explored further in large prospective studies. Trial registration: This study was prospectively registered in UMIN-CTR (UMIN000010150) on March 4th, 2013. |
| ArticleNumber | 596 |
| Audience | Academic |
| Author | Kasuya, Hideki Ohno, Eizaburo Kawashima, Hiroki Goto, Hidemi Villalobos, Itzel B. Koyama, Nobuto Kodera, Yasuhiro Ichinose, Toru Tanaka, Maki Naoe, Yoshinori Ishikawa, Takuya Hirooka, Yoshiki |
| Author_xml | – sequence: 1 givenname: Yoshiki surname: Hirooka fullname: Hirooka, Yoshiki email: hirooka@med.nagoya-u.ac.jp organization: Department of Endoscopy, Nagoya University Hospital – sequence: 2 givenname: Hideki surname: Kasuya fullname: Kasuya, Hideki organization: Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine – sequence: 3 givenname: Takuya surname: Ishikawa fullname: Ishikawa, Takuya organization: Department of Gastroenterology, Nagoya University Graduate School of Medicine – sequence: 4 givenname: Hiroki surname: Kawashima fullname: Kawashima, Hiroki organization: Department of Gastroenterology, Nagoya University Graduate School of Medicine – sequence: 5 givenname: Eizaburo surname: Ohno fullname: Ohno, Eizaburo organization: Department of Gastroenterology, Nagoya University Graduate School of Medicine – sequence: 6 givenname: Itzel B. surname: Villalobos fullname: Villalobos, Itzel B. organization: Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine – sequence: 7 givenname: Yoshinori surname: Naoe fullname: Naoe, Yoshinori organization: Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine – sequence: 8 givenname: Toru surname: Ichinose fullname: Ichinose, Toru organization: Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine – sequence: 9 givenname: Nobuto surname: Koyama fullname: Koyama, Nobuto organization: Takara Bio Inc – sequence: 10 givenname: Maki surname: Tanaka fullname: Tanaka, Maki organization: Takara Bio Inc – sequence: 11 givenname: Yasuhiro surname: Kodera fullname: Kodera, Yasuhiro organization: Department of Surgery II, Nagoya University Graduate School of Medicine – sequence: 12 givenname: Hidemi surname: Goto fullname: Goto, Hidemi organization: Department of Gastroenterology, Nagoya University Graduate School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29801474$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9k-9r1DAYx4tM3A_9A3wjAUEU7EzStMm9EY6xuYOB4tzrkKbpXY5ccibt4e2P8G_2qbe561ApbUry-X6Tfvs8x9mBD95k2UuCTwkR1YdEqBBljonIGSuL_PZJdkQYJzllmB_svR9mxyktMSZcYPEsO6QTgWGRHWU_p-jLQiWDZkg7661WDnXRwjO06PzmOp_3tjENsr6LqutXIcKS9UujOxv8AHULg4LXwW07q9HGxj69R5cXBKM2RNT7aBLAqnYGuQD2botUs1Feg-sahmjUINTDTHyePW2VS-bF3XiS3Vycfzu7zK8-f5qdTa9yzQvW5ZRQWmmMtVFYUwN3XQushOCFaiZK8QbrghEB6VQM14IoyrjhjFe8pZw0xUk22_k2QS3lOtqVilsZlJW_J0KcSxXhWM7IhiraYEMELVtGcVGzipd1w2pqaoXLGrw-7rzWfb0yjTZDVG5kOl7xdiHnYSPLCceswmDw9s4ghu-9SZ1c2aSNc8qb0CdJMSvhj8G2gL5-hC5DHz1EBVRZTUhBcPVAzRV8gPVtgH31YCqnJYNESMUoUKd_oeBqzMpqqLTWwvxI8G4kAKYzP7q56lOSs-uvY_bNHrswynWLFFw_VE0ag6_20_sT232JAsB3gI4hpWhaqW2nBh84rnWSYDk0g9w1g4RmkEMzyFtQkkfKe_P_aehOk4D1cxMfAv636BfCwBmC |
| CitedBy_id | crossref_primary_10_1097_MOO_0000000000000651 crossref_primary_10_1016_j_jinorgbio_2019_110815 crossref_primary_10_4103_jcrt_jcrt_91_21 crossref_primary_10_2958_suizo_38_247 crossref_primary_10_7759_cureus_40742 crossref_primary_10_3389_fmicb_2023_1188526 crossref_primary_10_1016_j_clinre_2019_02_014 crossref_primary_10_5946_ce_2019_003 crossref_primary_10_3748_wjg_v28_i21_2383 crossref_primary_10_1007_s13402_021_00587_z crossref_primary_10_1016_j_cytogfr_2020_07_008 crossref_primary_10_1016_j_biopha_2023_115627 crossref_primary_10_2174_1566523222666220921112753 crossref_primary_10_3390_cancers13051171 crossref_primary_10_1016_j_jconrel_2020_06_029 crossref_primary_10_3390_cancers12123514 crossref_primary_10_3390_cancers13164138 crossref_primary_10_1002_smll_202206948 crossref_primary_10_1016_j_clinthera_2018_11_003 crossref_primary_10_3390_v12111324 crossref_primary_10_3390_ijms21197073 crossref_primary_10_1080_14728222_2021_2010044 crossref_primary_10_3389_fonc_2020_00475 crossref_primary_10_3389_fimmu_2022_953410 crossref_primary_10_1007_s12328_021_01559_4 crossref_primary_10_1002_jhbp_944 crossref_primary_10_1016_j_ymthe_2020_10_023 crossref_primary_10_3389_fonc_2024_1525940 crossref_primary_10_1016_j_clinsp_2024_100348 crossref_primary_10_1007_s11894_020_00767_1 crossref_primary_10_2147_IDR_S334769 crossref_primary_10_1016_j_biomaterials_2020_120009 crossref_primary_10_3390_cancers15123235 crossref_primary_10_1111_den_13366 crossref_primary_10_1177_17562848241297434 crossref_primary_10_3389_fonc_2024_1446085 crossref_primary_10_3389_fonc_2023_1071751 crossref_primary_10_1016_j_giec_2023_08_004 crossref_primary_10_1016_j_cytogfr_2020_07_015 crossref_primary_10_1016_S1470_2045_24_00079_2 crossref_primary_10_3390_ijms21218310 crossref_primary_10_3390_biomedicines6040104 crossref_primary_10_36401_JIPO_22_8 crossref_primary_10_18794_aams_189655 crossref_primary_10_3390_vaccines11111717 crossref_primary_10_1002_chem_202302271 crossref_primary_10_1016_j_tranon_2022_101530 crossref_primary_10_1016_j_biopha_2020_110932 crossref_primary_10_1016_j_ymthe_2020_04_013 crossref_primary_10_1016_j_gie_2018_09_007 crossref_primary_10_1016_j_canlet_2018_10_045 crossref_primary_10_3389_fcimb_2022_921534 crossref_primary_10_12677_ACM_2023_133493 crossref_primary_10_4253_wjge_v14_i4_191 crossref_primary_10_3389_fimmu_2024_1383978 crossref_primary_10_3390_cancers15041116 crossref_primary_10_1002_path_6171 crossref_primary_10_1016_j_virusres_2019_197675 crossref_primary_10_1002_1878_0261_13603 crossref_primary_10_3389_fimmu_2024_1492464 crossref_primary_10_3390_v15030698 crossref_primary_10_1002_anie_202005458 crossref_primary_10_1080_1744666X_2022_2120471 crossref_primary_10_1021_acs_inorgchem_2c02557 crossref_primary_10_1053_j_seminoncol_2021_01_004 crossref_primary_10_1186_s13045_024_01561_6 crossref_primary_10_3390_microorganisms11112657 crossref_primary_10_3390_ijms26030994 crossref_primary_10_1016_j_pharmthera_2023_108521 crossref_primary_10_3390_cancers13040588 crossref_primary_10_1186_s12935_022_02583_1 crossref_primary_10_1093_oncolo_oyae200 crossref_primary_10_1634_theoncologist_2019_0438 crossref_primary_10_2147_OTT_S350136 crossref_primary_10_1038_s41598_020_61736_2 crossref_primary_10_3748_wjg_v28_i3_332 crossref_primary_10_3390_ijms21207505 crossref_primary_10_1186_s12967_023_04360_8 crossref_primary_10_3390_cancers15174265 crossref_primary_10_1016_j_jconrel_2022_10_004 crossref_primary_10_1016_j_ejca_2019_12_007 crossref_primary_10_37349_emed_2023_00168 crossref_primary_10_3389_fonc_2022_940019 crossref_primary_10_1016_j_omtm_2020_03_028 crossref_primary_10_1371_journal_pone_0239391 crossref_primary_10_1007_s11912_021_01057_3 crossref_primary_10_2174_1573394716666200211120906 crossref_primary_10_3390_cancers15164178 crossref_primary_10_1016_j_omto_2019_04_004 crossref_primary_10_3389_fonc_2022_875188 crossref_primary_10_1111_den_14815 crossref_primary_10_1002_jmv_26947 crossref_primary_10_3390_v13071200 crossref_primary_10_1007_s40883_023_00295_0 crossref_primary_10_1177_1178122X20913274 crossref_primary_10_1002_ange_202005458 crossref_primary_10_1007_s12274_021_4031_6 crossref_primary_10_1016_j_ebiom_2020_102786 crossref_primary_10_1016_j_bbcan_2020_188484 |
| Cites_doi | 10.1200/JCO.2006.07.9525 10.1200/JCO.2005.05.1490 10.3322/caac.21332 10.1200/JCO.2005.06.023 10.1038/sj.bjc.6603301 10.1586/14737140.2016.1168698 10.1093/annonc/mdh225 10.1200/JCO.2016.34.15_suppl.9543 10.1200/JCO.2002.11.149 10.1200/jco.2014.32.15_suppl.6082 10.1200/JCO.2006.07.0201 10.1056/NEJMoa1011923 10.1200/JCO.2003.02.098 10.1038/cgt.2010.65 10.1093/jjco/hyx075 10.1016/S1072-7515(99)00075-7 10.1200/JCO.2001.19.15.3447 10.1200/JCO.2004.10.112 10.1016/j.pan.2016.06.071 10.1056/NEJMoa1304369 10.1007/s00280-014-2509-6 10.1245/ASO.2006.08.035 10.1111/j.1349-7006.2010.01810.x 10.1038/gt.2011.141 10.1200/JCO.2004.12.082 10.1093/annonc/mdi309 10.1200/JCO.2006.09.0886 10.1200/JCO.1997.15.6.2403 10.1128/JVI.76.13.6718-6728.2002 10.1002/cncr.10323 10.1016/j.canlet.2010.01.034 10.3389/fonc.2017.00149 10.6004/jnccn.2017.0131 10.1158/1078-0432.CCR-08-2008 10.1002/ijc.26370 10.1007/s11912-007-0018-z 10.1038/cgt.2011.45 10.1080/00016480600702100 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2018 COPYRIGHT 2018 BioMed Central Ltd. Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2018 – notice: COPYRIGHT 2018 BioMed Central Ltd. – notice: Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12885-018-4453-z |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Acceso a contenido Full Text - Doaj |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_d2a2d0e1825f4203b4675bd4b2eba05b PMC5970460 A546401642 29801474 10_1186_s12885_018_4453_z |
| Genre | Pragmatic Clinical Trial Journal Article Clinical Trial, Phase I |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c734t-21226c00cea0c2e0c2bb80a8873ad9aa7d0c3418885640b81a247e74767f271d3 |
| IEDL.DBID | C6C |
| ISSN | 1471-2407 |
| IngestDate | Wed Aug 27 01:30:22 EDT 2025 Thu Aug 21 18:20:49 EDT 2025 Fri Sep 05 14:26:44 EDT 2025 Fri Jul 25 03:24:26 EDT 2025 Tue Jun 17 21:01:53 EDT 2025 Tue Jun 10 20:29:09 EDT 2025 Fri Jun 27 04:40:10 EDT 2025 Thu May 22 21:23:48 EDT 2025 Mon Jul 21 05:52:07 EDT 2025 Tue Jul 01 03:06:07 EDT 2025 Thu Apr 24 23:01:24 EDT 2025 Sat Sep 06 07:29:06 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Oncolytic virus EUS-guidance HF10 Pancreatic cancer |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c734t-21226c00cea0c2e0c2bb80a8873ad9aa7d0c3418885640b81a247e74767f271d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://doi.org/10.1186/s12885-018-4453-z |
| PMID | 29801474 |
| PQID | 2056913106 |
| PQPubID | 44074 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d2a2d0e1825f4203b4675bd4b2eba05b pubmedcentral_primary_oai_pubmedcentral_nih_gov_5970460 proquest_miscellaneous_2045298675 proquest_journals_2056913106 gale_infotracmisc_A546401642 gale_infotracacademiconefile_A546401642 gale_incontextgauss_ISR_A546401642 gale_healthsolutions_A546401642 pubmed_primary_29801474 crossref_citationtrail_10_1186_s12885_018_4453_z crossref_primary_10_1186_s12885_018_4453_z springer_journals_10_1186_s12885_018_4453_z |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-05-25 |
| PublicationDateYYYYMMDD | 2018-05-25 |
| PublicationDate_xml | – month: 05 year: 2018 text: 2018-05-25 day: 25 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC cancer |
| PublicationTitleAbbrev | BMC Cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2018 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | H Oettle (4453_CR26) 2005; 16 M Bhattacharyya (4453_CR33) 2011; 18 M Onimaru (4453_CR37) 2010; 294 RL Ferris (4453_CR11) 2014; 32 GP Stathopoulos (4453_CR28) 2006; 95 T Conroy (4453_CR31) 2011; 364 H Kimata (4453_CR7) 2006; 13 MA Tempero (4453_CR14) 2017; 15 L Kangasniemi (4453_CR35) 2012; 131 JD Berlin (4453_CR17) 2002; 20 RL Siegel (4453_CR1) 2016; 66 A Nakao (4453_CR8) 2004; 15 SF Sener (4453_CR3) 1999; 189 HA Burris 3rd (4453_CR15) 1997; 15 IR Eissa (4453_CR5) 2017; 7 E Van Cutsem (4453_CR29) 2004; 22 G Colucci (4453_CR18) 2002; 94 T Koshizuka (4453_CR6) 2002; 76 HL Kindler (4453_CR23) 2007; 9 MJ Moore (4453_CR25) 2003; 21 CM Rocha Lima (4453_CR27) 2004; 22 Y Fujimoto (4453_CR9) 2006; 126 V Heinemann (4453_CR21) 2006; 24 T Okusaka (4453_CR38) 2011; 102 SR Bramhall (4453_CR20) 2001; 19 G Cherubini (4453_CR34) 2011; 18 O Katopodis (4453_CR16) 2014; 74 GK Abou-Alfa (4453_CR19) 2006; 24 S Leitner (4453_CR36) 2009; 15 Y Hirooka (4453_CR13) 2016; 16 MJ Moore (4453_CR30) 2007; 25 S Myrehaug (4453_CR4) 2016; 16 J Furuse (4453_CR2) 2017; 47 A Nakao (4453_CR10) 2011; 18 DD Von Hoff (4453_CR32) 2013; 369 C Louvet (4453_CR24) 2005; 23 RHI Andtbacka (4453_CR12) 2016; 34 R Herrmann (4453_CR22) 2007; 25 |
| References_xml | – volume: 25 start-page: 1960 issue: 15 year: 2007 ident: 4453_CR30 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.07.9525 – volume: 24 start-page: 3946 issue: 24 year: 2006 ident: 4453_CR21 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.1490 – volume: 66 start-page: 7 issue: 1 year: 2016 ident: 4453_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21332 – volume: 23 start-page: 3509 issue: 15 year: 2005 ident: 4453_CR24 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.06.023 – volume: 95 start-page: 587 issue: 5 year: 2006 ident: 4453_CR28 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603301 – volume: 16 start-page: 523 issue: 5 year: 2016 ident: 4453_CR4 publication-title: Expert Rev Anticancer Ther doi: 10.1586/14737140.2016.1168698 – volume: 15 start-page: 988 issue: 6 year: 2004 ident: 4453_CR8 publication-title: Ann Oncol doi: 10.1093/annonc/mdh225 – volume: 34 start-page: 9543 issue: 15 Suppl year: 2016 ident: 4453_CR12 publication-title: J Clin Oncol doi: 10.1200/JCO.2016.34.15_suppl.9543 – volume: 20 start-page: 3270 issue: 15 year: 2002 ident: 4453_CR17 publication-title: J Clin Oncol doi: 10.1200/JCO.2002.11.149 – volume: 32 start-page: 6082 issue: 15 Suppl year: 2014 ident: 4453_CR11 publication-title: J Clin Oncol doi: 10.1200/jco.2014.32.15_suppl.6082 – volume: 24 start-page: 4441 issue: 27 year: 2006 ident: 4453_CR19 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.07.0201 – volume: 364 start-page: 1817 issue: 19 year: 2011 ident: 4453_CR31 publication-title: N Engl J Med doi: 10.1056/NEJMoa1011923 – volume: 21 start-page: 3296 issue: 17 year: 2003 ident: 4453_CR25 publication-title: J Clin Oncol doi: 10.1200/JCO.2003.02.098 – volume: 18 start-page: 167 issue: 3 year: 2011 ident: 4453_CR10 publication-title: Cancer Gene Ther doi: 10.1038/cgt.2010.65 – volume: 47 start-page: 1 issue: 9 year: 2017 ident: 4453_CR2 publication-title: Jpn J Clin Oncol doi: 10.1093/jjco/hyx075 – volume: 189 start-page: 1 issue: 1 year: 1999 ident: 4453_CR3 publication-title: J Am Coll Surg doi: 10.1016/S1072-7515(99)00075-7 – volume: 19 start-page: 3447 issue: 15 year: 2001 ident: 4453_CR20 publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.15.3447 – volume: 22 start-page: 1430 issue: 8 year: 2004 ident: 4453_CR29 publication-title: J Clin Oncol doi: 10.1200/JCO.2004.10.112 – volume: 16 start-page: S17 issue: 4, Supplement year: 2016 ident: 4453_CR13 publication-title: Pancreatology doi: 10.1016/j.pan.2016.06.071 – volume: 369 start-page: 1691 issue: 18 year: 2013 ident: 4453_CR32 publication-title: N Engl J Med doi: 10.1056/NEJMoa1304369 – volume: 74 start-page: 333 issue: 2 year: 2014 ident: 4453_CR16 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-014-2509-6 – volume: 13 start-page: 1078 issue: 8 year: 2006 ident: 4453_CR7 publication-title: Ann Surg Oncol doi: 10.1245/ASO.2006.08.035 – volume: 102 start-page: 425 issue: 2 year: 2011 ident: 4453_CR38 publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2010.01810.x – volume: 18 start-page: 1157 issue: 12 year: 2011 ident: 4453_CR34 publication-title: Gene Ther doi: 10.1038/gt.2011.141 – volume: 22 start-page: 3776 issue: 18 year: 2004 ident: 4453_CR27 publication-title: J Clin Oncol doi: 10.1200/JCO.2004.12.082 – volume: 16 start-page: 1639 issue: 10 year: 2005 ident: 4453_CR26 publication-title: Ann Oncol doi: 10.1093/annonc/mdi309 – volume: 25 start-page: 2212 issue: 16 year: 2007 ident: 4453_CR22 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.0886 – volume: 15 start-page: 2403 issue: 6 year: 1997 ident: 4453_CR15 publication-title: J Clin Oncol doi: 10.1200/JCO.1997.15.6.2403 – volume: 76 start-page: 6718 issue: 13 year: 2002 ident: 4453_CR6 publication-title: J Virol doi: 10.1128/JVI.76.13.6718-6728.2002 – volume: 94 start-page: 902 issue: 4 year: 2002 ident: 4453_CR18 publication-title: Cancer doi: 10.1002/cncr.10323 – volume: 294 start-page: 178 issue: 2 year: 2010 ident: 4453_CR37 publication-title: Cancer Lett doi: 10.1016/j.canlet.2010.01.034 – volume: 7 start-page: 149 year: 2017 ident: 4453_CR5 publication-title: Front Oncol doi: 10.3389/fonc.2017.00149 – volume: 15 start-page: 1028 issue: 8 year: 2017 ident: 4453_CR14 publication-title: J Natl Compr Cancer Netw doi: 10.6004/jnccn.2017.0131 – volume: 15 start-page: 1730 issue: 5 year: 2009 ident: 4453_CR36 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-2008 – volume: 131 start-page: 253 issue: 1 year: 2012 ident: 4453_CR35 publication-title: Int J Cancer doi: 10.1002/ijc.26370 – volume: 9 start-page: 170 issue: 3 year: 2007 ident: 4453_CR23 publication-title: Curr Oncol Rep doi: 10.1007/s11912-007-0018-z – volume: 18 start-page: 734 issue: 10 year: 2011 ident: 4453_CR33 publication-title: Cancer Gene Ther doi: 10.1038/cgt.2011.45 – volume: 126 start-page: 1115 issue: 10 year: 2006 ident: 4453_CR9 publication-title: Acta Otolaryngol doi: 10.1080/00016480600702100 |
| SSID | ssj0017808 |
| Score | 2.5432081 |
| Snippet | Background
Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising... Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all... Background Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising... Abstract Background Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 596 |
| SubjectTerms | Adult Aged Analysis Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor activity Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Care and treatment Chemotherapy Clinical trials Combined Modality Therapy - adverse effects Combined Modality Therapy - methods Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Drug dosages Duodenum Endosonography Erlotinib Hydrochloride - therapeutic use EUS-guidance Female Gemcitabine Health Promotion and Disease Prevention Herpes simplex Herpesvirus 1, Human - genetics HF10 Humans immunity and cancer vaccines Infection Injection Injections, Intralesional - methods Male Medical prognosis Medicine/Public Health Metastasis Middle Aged Mutation Myelosuppression Oncology Oncolysis Oncolytic viral therapy Oncolytic Virotherapy - adverse effects Oncolytic Virotherapy - methods Oncolytic virus Oncolytic Viruses - genetics Pancreas - diagnostic imaging Pancreas - pathology Pancreatic cancer Pancreatic Neoplasms Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pancreatic Neoplasms - therapy Patients Prognosis Progression-Free Survival Research Article Surgical Oncology Survival Survival Rate Toxicity Treatment Outcome Tumors Ultrasonography, Interventional Ultrasound Young Adult |
| SummonAdditionalLinks | – databaseName: Acceso a contenido Full Text - Doaj dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k1KAYOQkICojuM43uOCWm2RihBlpd4sx492UUnQ7gap_RH8ZmacZGmKgAuHPaw9Wcee8Tx2xp8JeVGYnEOMJtMqMyEV0rl0MjEqdYoH4SchBI9_6B9-kLO5eH9cHF-66gtrwjp44G7hdh033DEPbnARBGd5BTu7qJyoYAjDigq1L9i8IZjq8welYqrPYWZK7q5ACyssUlOpEEWeXoysUATr_10lX7JJV-slryRNoy3av0Vu9k4knXYvf5tc8_Udcv2wT5PfJT-m9OMpmCd6QIeTjzRez0GbQPfmR-lJu3De0QUOtG6_4il9-PIllmXVSARuIW1qEJJzGIJ-Xyzb1Rs6g-ibgpNL24gRZNd47IpGa3h2TodqAgr6pXNFLbXYsrxH5vt7n9_N0v7ihdSWuVinYM64tIxZb5jlHj5VpZgBfZQbNzGmdMyC9YPguZCCVSozXJQeAhNZBl5mLr9Ptuqm9g8JhR8orKpMFrwT0pYKEf-8ktarUAaZJYQNjNC2RyXHyzHOdIxOlNQd7zTwTiPv9EVCXm0e-dZBcvyN-C1yd0OIaNqxAWRM9zKm_yVjCXmKsqG7o6kbnaCnhYD5Q8DJE_I8UiCiRo0lOyemXa30wdGnEdHLnig0MEdr-hMQsFIIwjWi3BlRwpa34-5BSHWvclaagys7ycBblwl5tunGJ7GMrvZNizSYZ1cwu4Q86GR6szLQDuFyKRJSjqR9tHTjnnpxGgHJISjF_HpCXg_74tdr_ZEz2_-DM4_IDY67Olag7pCt9bL1j8FLXFdPokL4CX7EY54 priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3bbtMw1IJOQrwg7gQGGISEBETLxXbcJ9ShTR3Spmmj0t4sx3a6opGMpkHaPoJv5pzEzcgQe-hD7ZOm9rn7XEzIO67TBHw0EeaxLkImrA3HYy1DK5OCuXFRFA4P9PcPxHTGvp7wE3_gVvu0yrVMbAW1rQyekYOTzsU4BmNEfD7_GeKtURhd9Vdo3CYbIIIlH5GN7Z2Dw6M-jpDJSPpYZizFVg1AEpPVZMgYT8PLgTZqm_b_K5r_0k3X8yavBU9bnbR7n9zzxiSddNh_QG658iG5s-_D5Y_I7wk9PAU1RffougKSttd00KqgO7PjcN4srLN0gS9aNT-wWh--fG_Ts0oEAvOQViUQywW8gv5aLJv6E52CF07B2KVN2yvIrLD8irZa8eyCrrMKKMiZziQ11ODI8jGZ7e58-zIN_QUMoclStgphTxNhosg4HZnEwSfPZaRBLqXajrXObGRAC4ITzQWLchnrhGUOHBSRFUkW2_QJGZVV6Z4RCj_Ajcx1XDjLhMkkdv5zUhgni6wQcUCiNSKU8d3J8ZKMM9V6KVKoDncKcKcQd-oyIB_6R8671hw3AW8jdntA7KrdDlTLufJMqmyiExs5cLl4wZIozUGL8NyyHMhZRzwPyGukDdWVqPayQU04g_WD45kE5G0LgZ01SkzdmeumrtXe8dEA6L0HKipYo9G-EgJ2CptxDSA3B5DA-mY4vSZS5UVPra4YJSBv-ml8EtPpSlc1CIPxdgmrC8jTjqb7nYFxcJszFpBsQO2DrRvOlIvTtjE5OKcYZw_IxzVfXP2t_2Lm-c2LeEHuJsivEQ8TvklGq2XjXoIduMpfeWb_A-qSXDU priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3bbtMw1BpDQrwg7gQGGISEBGQ4juO4DwgVtKlDKkKMSnuzHF-6opJA2yC6j-CbOXaSjoyBxEMfah83tc8952KEnmQqpeCj8bhIlIsZNyYeDJSIjaCO2YFzzvoX-uP3fDRh746yoy3UXW_VHuDyXNfO3yc1Wcx3f3xbvwaGfxUYXvCXS5CxwqegiZixLI1PLqCLoJi4J_IxOw0q5IKINrB57rKeagod_P-U078pqrNJlGciqUFB7V9FV1rLEg8bUriGtmx5HV0at7HzG-jnEH84Bp2FD3BXDonDnR24cnhvchhP65mxBs_8g1b1F1-6D18-h1yt0gOBrYirEihnDY_A32eLevkCj8Alx2D54jo0DtIrX4uFg4qcr3GXYoBB6DT2qcbajyxuosn-3qe3o7i9jSHWecpWMeg4yjUh2iqiqYVPUQiiQEilygyUyg3RoBLBo844I4VIFGW5BW-F547miUlvoe2yKu0dhOEHMi0KlThrGNe58G0AreDaCpc7nkSIdIiQum1V7m_MmMvgsgguG9xJwJ30uJMnEXq2WfK16dPxL-A3HrsbQN9iOwxUi6lsOVYaqqghFvyvzDFK0gJUSlYYVgBtK5IVEXroaUM29aobQSGHGYP9gxdKI_Q4QPg2G6XP45mqermUB4cfe0BPWyBXwR61assi4KR8Z64e5E4PEuSA7k93RCo7NpIU7NtBAiY8j9CjzbRf6XPrSlvVHsYH3wXsLkK3G5renAyMgw-dswjlPWrvHV1_ppwdhy7l4Kn6oHuEnnd8cfq3_oqZu_8FfQ9dpp59SRbTbAdtrxa1vQ824qp4EDj_F-isYog priority: 102 providerName: Scholars Portal |
| Title | A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer |
| URI | https://link.springer.com/article/10.1186/s12885-018-4453-z https://www.ncbi.nlm.nih.gov/pubmed/29801474 https://www.proquest.com/docview/2056913106 https://www.proquest.com/docview/2045298675 https://pubmed.ncbi.nlm.nih.gov/PMC5970460 https://doaj.org/article/d2a2d0e1825f4203b4675bd4b2eba05b |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1ra9swUKwtjH0Ze89bl2ljMNhmasuSrHxMSko6SCnpAmVfhCzJbUbnjCQetD9iv3l3tuPV3QP2IYJIpzjSne7he4iQN8IkDGw0GWaxyUMunQv7faNCp1jOfT_Pc48v9CdHcjzjH0_FaVMsGnNhrvvvYyX3VsA_FYaXqZBzkYRXW2RHYJkx9MvK_dZhkKpINU7LP07riJ2qOv_vPPiaELoZIHnDS1oJn4N75G6jNdJBjeb75JYvHpDbk8Yv_pD8GNDjc5BH9JBuUh1pdR8HXeR0NDsJz8q5847O8UHr8ium5cOXL1UcVoFAoAfSRQFUcQmPoN_ny3L1gY7B3Kag1dKyKgpk15hnRSvxd3FJN-EDFBhKrXtaarFn-YjMDkaf9sdhc9NCaNOEr0OQX0zaKLLeRJZ5-GSZigwwoMS4vjGpiyyIO7CWheRRpmLDeOrBEpFpztLYJY_JdrEo_FNC4QeEVZmJc--4tKnCEn9eSetVnuYyDki0QYS2TRlyvA3jQlfmiJK6xp0G3GnEnb4KyLt2yre6Bse_gIeI3RYQy2dXHUBVujmN2jHDXOTBthI5Z1GSgbgQmeMZ0K2JRBaQl0gbus5FbZmAHggO6wcLkwXkdQWBJTQKjNE5M-VqpQ9Pph2gtw1QvoA1WtOkPMBOYdWtDuRuBxLOuO0Ob4hUNzxmpRnorv0Y1HMZkFftMM7EuLnCL0qEQce6gtUF5ElN0-3OQD_YxykPSNqh9s7WdUeK-XlVgRysUHSoB-T95lz8-lt_xcyz_4J-Tu4wPL6RCJnYJdvrZelfgP63znpkKz1Ne2RnODo6nvYqPtCr3qVAO-EK2unwM7QzNvgJ5dVaQw |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQw0CqtBFwQbwKFGgRCokQkXsfxHhDawla79KGq7Uq9Gcd22kUlKbsbUPsRfArfyEweW1JEbz3sYe3Jw553ZjxDyMtIdxj4aMJPQp36XFjrd7ta-laylLtumqYOP-hvbYvBiH8-iA4WyO_mLAymVTYysRTUNjf4jRyc9Eh0QzBGxIeT7z52jcLoatNCoyKLDXf6E1y26fvhJ8DvK8bW-_sfB37dVcA3cYfPfJDVTJggME4Hhjn4JYkMNDBbR9uu1rENDIh28AwjwYNEhprx2IHVLeKUxaHtwH2vkSUwM7rARUtr_e2d3XncIpaBrGOnoRTvpiD9JSbHSZ_zqOOftbRf2STgX1Xwly68mKd5IVhb6sD12-RWbbzSXkVtd8iCy-6S61t1eP4e-dWjO0egFumQNicuadkWhOYp7Y_2_MNibJ2lY3zQrPiG1QHgz9cyHSxDIDBHaZ4BcZ7CI-iP8aSYvqUD8PopGNe0KGsTmRke96KlFj4-pU0WAwW5VpnAhhocmdwnoytBzQOymOWZe0Qo3CAyMtFh6iwXJpZYadBJYZxM41SEHgkaRChTV0PHphzHqvSKpFAV7hTgTiHu1JlH3swvOalKgVwGvIbYnQNiFe9yIJ8cqlooKMs0s4EDFy9KOQs6CWitKLE8AfbRQZR4ZAVpQ1VHYueySPUiDusHR5d55EUJgZU8MkwVOtTFdKqGe7stoNc1UJrDGo2uT17ATmHxrxbkcgsSRI1pTzdEqmpRN1XnjOmR5_NpvBLT9zKXFwiD8X0Jq_PIw4qm5zsD4-Cmx9wjcYvaW1vXnsnGR2UhdHCGMa7vkdWGL85f67-YeXz5IlbIjcH-1qbaHG5vPCE3GfJuEPksWiaLs0nhnoINOkue1YxPyZerljV_AM8_l54 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3bbtMw1IJOmnhB3AkMZhASEhAtcRzHfSywqi1smiiT9mY5vnRFI5maBGn7CL6Z49wg4yLx0Ifax03tc8-5GKEXsYwI-GjMT0Npfcq09sdjyX3NiaVmbK017oX-wSGbHdPFSXzS3nNadNnuXUiyqWlwXZqycu9c24bFOdsrQKpyl3TGfUrjyL-8jrY4A-thhLYmk8Vy0QcSEh7wNpj5x4UDdVR37f9dNv-inK4mTl6JntZKaXoL3WytSTxp0H8bXTPZHbR90MbL76LvE3x0CnoKz3FXAonrezpwbvH-8dJfVWttNF67B5XVV1euD1--1PlZmQMC-xDnGVDLBTwCf1tvquINnoEbjsHaxVXdLEiVrv4K12rx7AJ3aQUYBE1jkyqs3MjmHjqe7n9-N_PbGxh8lUS09EGvEaaCQBkZKGLgk6Y8kCCYIqnHUiY6UKAGwYuOGQ1SHkpCEwMeCkssSUId3UejLM_MQ4ThB2LFUxlaoylTCXet_wxnynCbWBZ6KOgQIVTbntzdknEmajeFM9HgTgDuhMOduPTQq37JedOb41_Abx12e0DXVrseyDcr0XKp0EQSHRjwuWJLSRCloEbiVNMU6FkGceqhXUcboqlR7YWDmMQU9g-eJ_HQ8xrCtdbIXO7OSlZFIebLTwOgly2QzWGPSralEHBSrhvXAHJnAAm8r4bTHZGKVvYUgoBNOw7BbGceetZPu5Uuny4zeeVgXMCdw-489KCh6f5kYBz85oR6KBlQ--DohjPZ-rTuTA7eqQu0e-h1xxc__9ZfMfPov6B30fbR-6n4OD_88BjdII6Tg9gn8Q4alZvKPAETsUyftmLgB75sYJY |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Phase+I+clinical+trial+of+EUS-guided+intratumoral+injection+of+the+oncolytic+virus%2C+HF10+for+unresectable+locally+advanced+pancreatic+cancer&rft.jtitle=BMC+cancer&rft.au=Hirooka%2C+Yoshiki&rft.au=Kasuya%2C+Hideki&rft.au=Ishikawa%2C+Takuya&rft.au=Kawashima%2C+Hiroki&rft.date=2018-05-25&rft.pub=BioMed+Central&rft.eissn=1471-2407&rft.volume=18&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-018-4453-z&rft.externalDocID=10_1186_s12885_018_4453_z |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |